CN111373034A - 重组尿酸酶 - Google Patents

重组尿酸酶 Download PDF

Info

Publication number
CN111373034A
CN111373034A CN201880054605.5A CN201880054605A CN111373034A CN 111373034 A CN111373034 A CN 111373034A CN 201880054605 A CN201880054605 A CN 201880054605A CN 111373034 A CN111373034 A CN 111373034A
Authority
CN
China
Prior art keywords
uricase
candida utilis
recombinant mutant
replaced
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880054605.5A
Other languages
English (en)
Chinese (zh)
Inventor
雅迪蒂·R·德斯班德
丹妮卡·格鲁伊奇
斯瑞达·戈文达拉扬
马克·韦尔奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elena Pharmaceutical Co ltd
Original Assignee
Elena Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elena Pharmaceutical Co ltd filed Critical Elena Pharmaceutical Co ltd
Publication of CN111373034A publication Critical patent/CN111373034A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048—Uricase (1.7.3.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201880054605.5A 2017-07-07 2018-07-06 重组尿酸酶 Pending CN111373034A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762529726P 2017-07-07 2017-07-07
US62/529,726 2017-07-07
US201862678511P 2018-05-31 2018-05-31
US62/678,511 2018-05-31
PCT/US2018/041015 WO2019010369A1 (en) 2017-07-07 2018-07-06 RECOMBINANT ENZYME URICASE

Publications (1)

Publication Number Publication Date
CN111373034A true CN111373034A (zh) 2020-07-03

Family

ID=64951239

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880054605.5A Pending CN111373034A (zh) 2017-07-07 2018-07-06 重组尿酸酶

Country Status (8)

Country Link
US (2) US20200308534A1 (enExample)
EP (1) EP3655527A4 (enExample)
JP (2) JP2020530282A (enExample)
CN (1) CN111373034A (enExample)
AU (1) AU2018297309A1 (enExample)
CA (1) CA3069197A1 (enExample)
IL (1) IL271813A (enExample)
WO (1) WO2019010369A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118497162A (zh) * 2024-05-24 2024-08-16 广东少和生物科技有限公司 黑酵母菌尿酸氧化酶及其突变体和应用
CN119876069A (zh) * 2025-03-12 2025-04-25 开平牵牛生化制药有限公司 具有高活性且免疫原性弱化的人源尿酸氧化酶突变体
CN119876071A (zh) * 2025-03-12 2025-04-25 开平牵牛生化制药有限公司 低免疫原性的高活性人源尿酸氧化酶突变体

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
WO2021173808A1 (en) * 2020-02-25 2021-09-02 Synlogic Operating Company, Inc. Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof
KR20230110281A (ko) 2020-11-03 2023-07-21 프로탈릭스 리미티드 변형된 유리카제(uricase) 및 이의 용도
CN114480320B (zh) * 2022-02-28 2024-01-16 复旦大学 重组夜猴尿酸酶及其应用

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0956383A (ja) * 1995-08-24 1997-03-04 Kikkoman Corp 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体ｄｎａ及び変異型ウリカーゼの製造法
CN1561390A (zh) * 2001-08-02 2005-01-05 菲尼克斯药物股份有限公司 Peg修饰的尿酸酶
US20050049166A1 (en) * 2003-08-29 2005-03-03 Huang Tsao-Chin Clare Enzyme-based cleaning composition and method of use
CN1980687A (zh) * 2004-02-09 2007-06-13 人类基因科学公司 清蛋白融合蛋白
US20080175834A1 (en) * 2003-11-15 2008-07-24 Astrazenca Ab Carboxypertidase U (Cpu) Mutants
CN101390969A (zh) * 2008-11-03 2009-03-25 中国人民解放军军事医学科学院生物工程研究所 降低血液中尿酸浓度的药物
CN101875922A (zh) * 2009-04-30 2010-11-03 重庆医科大学 来自苛求芽孢杆菌的两种尿酸酶和其突变体及它们的聚乙二醇修饰与应用
CN102586315A (zh) * 2012-02-21 2012-07-18 章泽人 一种低尿酸分泌量益生菌及其制备方法
CN104342415A (zh) * 2014-07-08 2015-02-11 吉林省金梓源生物科技有限公司 一种重组尿酸酶的制备方法
TW201618773A (zh) * 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
CN107308452A (zh) * 2017-05-29 2017-11-03 钟术光 一种稳定生物活性材料的组合物的制备方法
DE112011105840B3 (de) * 2010-02-05 2018-07-12 New England Biolabs, Inc. Restriktionsendonukleasen mit hoher Genauigkeit
WO2019038555A2 (en) * 2017-08-25 2019-02-28 The University Of Birmingham TAT EXPRESSION SYSTEM
CN109846909A (zh) * 2019-01-31 2019-06-07 武汉康复得生物科技股份有限公司 可在肠道中催化尿酸降解的组合物及其制备方法和应用
EP3967754A1 (en) * 2019-05-10 2022-03-16 Peg-Bio Biopharm Co., Ltd. (Chongqing) Polyethylene glycol-modified urate oxidase

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PT2158923E (pt) 1998-08-06 2013-06-04 Univ Duke Conjugados de peg-urato oxidase e sua utilização
US8557831B2 (en) 2004-07-21 2013-10-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of insulin resistance
EP2013225B1 (en) 2006-04-12 2014-12-17 Crealta Pharmaceuticals LLC Purification of proteins with cationic surfactant
EP2271750A4 (en) * 2008-03-24 2011-07-27 Althea Technologies Inc URICASE COMPOSITIONS AND METHODS OF USE
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
WO2014170916A2 (en) * 2013-04-17 2014-10-23 Council Of Scientific & Industrial Research Novel uricase mutants
CN106554948B (zh) 2015-09-29 2019-06-25 上海生物制品研究所有限责任公司 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用
WO2017156513A1 (en) 2016-03-11 2017-09-14 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
JP2019535819A (ja) 2016-11-11 2019-12-12 ホライゾン ファーマ リューマトロジー リミテッド ライアビリティ カンパニーＨｏｒｉｚｏｎ Ｐｈａｒｍａ Ｒｈｅｕｍａｔｏｌｏｇｙ Ｌｌｃ プレドニゾンおよびウリカーゼ分子の併用療法ならびにその使用
AU2018236123B2 (en) 2017-03-11 2024-04-18 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CN109223707B (zh) 2018-09-13 2020-12-08 中国药科大学 一种尿酸酶外用凝胶制剂、其制备方法及用途

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0956383A (ja) * 1995-08-24 1997-03-04 Kikkoman Corp 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体ｄｎａ及び変異型ウリカーゼの製造法
US5700674A (en) * 1995-08-24 1997-12-23 Kikkoman Corporation Mutant uricase, a mutant uricase gene, a novel recombinant DNA, and a process for producing mutant uricase
CN1561390A (zh) * 2001-08-02 2005-01-05 菲尼克斯药物股份有限公司 Peg修饰的尿酸酶
US20050049166A1 (en) * 2003-08-29 2005-03-03 Huang Tsao-Chin Clare Enzyme-based cleaning composition and method of use
US20080175834A1 (en) * 2003-11-15 2008-07-24 Astrazenca Ab Carboxypertidase U (Cpu) Mutants
CN1980687A (zh) * 2004-02-09 2007-06-13 人类基因科学公司 清蛋白融合蛋白
CN101390969A (zh) * 2008-11-03 2009-03-25 中国人民解放军军事医学科学院生物工程研究所 降低血液中尿酸浓度的药物
CN101875922A (zh) * 2009-04-30 2010-11-03 重庆医科大学 来自苛求芽孢杆菌的两种尿酸酶和其突变体及它们的聚乙二醇修饰与应用
DE112011105840B3 (de) * 2010-02-05 2018-07-12 New England Biolabs, Inc. Restriktionsendonukleasen mit hoher Genauigkeit
CN102586315A (zh) * 2012-02-21 2012-07-18 章泽人 一种低尿酸分泌量益生菌及其制备方法
CN104342415A (zh) * 2014-07-08 2015-02-11 吉林省金梓源生物科技有限公司 一种重组尿酸酶的制备方法
TW201618773A (zh) * 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
CN107308452A (zh) * 2017-05-29 2017-11-03 钟术光 一种稳定生物活性材料的组合物的制备方法
WO2019038555A2 (en) * 2017-08-25 2019-02-28 The University Of Birmingham TAT EXPRESSION SYSTEM
CN109846909A (zh) * 2019-01-31 2019-06-07 武汉康复得生物科技股份有限公司 可在肠道中催化尿酸降解的组合物及其制备方法和应用
EP3967754A1 (en) * 2019-05-10 2022-03-16 Peg-Bio Biopharm Co., Ltd. (Chongqing) Polyethylene glycol-modified urate oxidase

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
NCBI: "RecName: Full=Uricase; AltName: Full=Urate oxidase" *
TRUSZKOWSKI 等 *
YASUJI KOYAMA 等: "Cloning, Sequence Analysis, and Expression in Escherichia coli of the Gene Encoding the Candida utilis Urate Oxidase (Uricase)" *
卢彦敏;王霞;付正菊;宋娓;李长贵;付爱荣;: "雌激素与人尿酸盐转运子(hUAT)基因表达的相关性研究" *
苏毕・阿吉;尹洪超;: "可溶性高尿酸对人脐静脉内皮细胞NLRP3炎性体途径的影响" *
赵兴秀;何义国;姚兴川;杜林方;孟延发;: "PEG-重组酵母尿酸酶结合物的基本特性研究" *
连希艳;张瑜;赵劲涛;黄胜华;李江;: "不同浓度尿酸对大鼠肾小球内皮细胞增殖、NO合成及ET-1分泌的影响" *
钱文雨 等: "产朊假丝酵母(Candida utilis)尿酸酶的基本特性" *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118497162A (zh) * 2024-05-24 2024-08-16 广东少和生物科技有限公司 黑酵母菌尿酸氧化酶及其突变体和应用
CN119876069A (zh) * 2025-03-12 2025-04-25 开平牵牛生化制药有限公司 具有高活性且免疫原性弱化的人源尿酸氧化酶突变体
CN119876071A (zh) * 2025-03-12 2025-04-25 开平牵牛生化制药有限公司 低免疫原性的高活性人源尿酸氧化酶突变体
CN119876069B (zh) * 2025-03-12 2025-10-21 开平牵牛生化制药有限公司 具有高活性且免疫原性弱化的人源尿酸氧化酶突变体

Also Published As

Publication number Publication date
US20200308534A1 (en) 2020-10-01
EP3655527A4 (en) 2021-06-16
AU2018297309A1 (en) 2020-01-30
US20200071681A1 (en) 2020-03-05
EP3655527A1 (en) 2020-05-27
JP2020530282A (ja) 2020-10-22
WO2019010369A1 (en) 2019-01-10
IL271813A (en) 2020-02-27
CA3069197A1 (en) 2019-01-10
US10815461B2 (en) 2020-10-27
JP2023126877A (ja) 2023-09-12

Similar Documents

Publication Publication Date Title
CN111373034A (zh) 重组尿酸酶
KR102076348B1 (ko) 사람 아르기나제 및 부위-지향성 페길화된 사람 아르기나제 및 그의 용도
CN111499725A (zh) 结合IL-4受体α的泪脂质运载蛋白突变蛋白
JP7711967B2 (ja) 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法
EP3807408A1 (en) Methods of making alkaline phosphatase agents
JP7590401B2 (ja) 改変されたｅｓｃｈｅｒｉｃｈｉａ ｃｏｌｉ株ｎｉｓｓｌｅ及び胃腸障害の処置
CN116836233B (zh) 抗炎活性多肽及其应用
CN114075296A (zh) 一种多功能变体蛋白及其融合蛋白
US9956240B2 (en) Therapeutic monosaccharide-based inhibitors of hexokinase and glucokinase for parasitic diseases, along with methods of their formation and use
WO2022095973A1 (zh) 尿酸氧化酶制剂及其应用
CN110121340A (zh) 聚乙二醇化精氨酸脱亚氨酶的调配物
EP2296683B1 (en) AvrA PROTEIN FOR TREATING INFLAMMATORY INTESTINAL DISEASE AND MANAGING SYMPTOMS THEREOF
CN105693864A (zh) 一种三聚体trail蛋白及其应用
WO2019136139A2 (en) Antimicrobial peptides and use thereof
JP5892648B2 (ja) Ｄｄｓカプセル用タンパク質およびそれを用いた薬剤とその調整方法
CN116888258A (zh) 修饰的红细胞及其治疗高尿酸血症和痛风的用途
US20210309984A1 (en) ChiA Enzyme
TW201808987A (zh) Ｇｍ－ｃｓｆ變體及使用方法
CN117603934B (zh) 一种尿酸酶的纯化方法
CN104311656A (zh) cFGF-21蛋白及其在治疗类风湿关节炎中的应用
US20220378886A1 (en) Methods of treating hyperoxaluria
CN116789751A (zh) 预防和/或治疗纤维化疾病的多肽及其应用
WO2025002334A1 (zh) 尿酸氧化酶及其聚乙二醇化缀合物的稳定剂及其药物用途
WO2007041964A1 (fr) Utilisation de recepteur long du facteur de necrose tumorale alpha soluble recombinant humain de demi-vie dans la preparation de medicament pouvant prevenir l'insuffisance hepatique
CN116731945A (zh) 一种表达酪氨酸解氨酶SeSam8的重组大肠杆菌及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200703

WD01 Invention patent application deemed withdrawn after publication